ArticleInternational journal of biomedical investigation2018
Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application.
Article in International journal of biomedical investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- A PRISMA-guided systematic review of pharmacogenetic anticancer clinical trials registered on clinicaltrials.gov.Medicine · 2026Pooled it
- Quality-of-life measures in pharmacogenomic studies: a systematic review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Pooled it
- Evidence level for pharmacogenetic testing in antidepressant treatment: a systematic review.PharmacogenomicsPooled it
- Drug Brand Switching: A Regulatory Perspective.Drug safety · 2026Review
- Article
- Pharmacological Approaches and Innovative Strategies for Individualized Patient Care.Recent patents on biotechnology · 2026Review
- Point of Care Testing, Rapid Next Generation Sequencing and Artificial Intelligence in Pediatric and Neonatal Healthcare: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- TPMT and HLA-DQ Allelic Variants in Relation to Drug Response, Safety and Need for Therapy Optimization in Pediatric Inflammatory Bowel Disease.Children (Basel, Switzerland) · 2025Article
- How Clinical Pharmacology Can Support Clinical Trial Diversity and Inclusion.Clinical and translational science · 2025Review
- Treatment Strategies for Cutaneous and Oral Mucosal Side Effects of Oncological Treatment in Breast Cancer: A Comprehensive Review.Biomedicines · 2025Review
- Large Language Models in Genomics-A Perspective on Personalized Medicine.Bioengineering (Basel, Switzerland) · 2025Review
- The Polygenic Nature of Multiple Sclerosis: Genetic Variants, Immunological Modulation, and Environmental Connections.Endocrine, metabolic & immune disorders drug targets · 2025Review
- Microfluidics as a promising technology for personalized medicine.BioImpacts : BI · 2025Review
- Advancements in pathology: Digital transformation, precision medicine, and beyond.Journal of pathology informatics · 2025Review
- Deciphering single-cell gene expression variability and its role in drug response.Human molecular genetics · 2024Article
- Article
- Navigating Drug-Induced Lung Disease (DILD): A Comprehensive Review on Management and Prevention Strategies.Cureus · 2024Review
- Pharmacogenomics: A Genetic Approach to Drug Development and Therapy.Pharmaceuticals (Basel, Switzerland) · 2024Review
- From Drug Discovery to Drug Approval: A Comprehensive Review of the Pharmacogenomics Status Quo with a Special Focus on Egypt.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Investigation of community pharmacists' knowledge and attitudes of pharmacogenomics testing: implication for improved pharmacogenomic testing practice.Human genomics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Since the human genome project in 2003, the view of personalized medicine to improve diagnosis and cure diseases at the molecular level became more real. Sequencing the human genome brought some benefits in medicine such as early detection of diseases with a genetic predisposition, treating patients with rare diseases, the design of gene therapy and the understanding of pharmacogenetics in the metabolism of drugs. This review explains the concepts of pharmacogenetics, polymorphisms, mutations, variations, and alleles, and how this information has helped us better understand the metabolism of drugs. Multiple resources are presented to promote reducing the gap between scientists, physicians, and patients in understanding the use and benefits of pharmacogenetics. Some of the most common clinical examples of genetic variants and how pharmacogenetics was used to determine treatment options for patients having these variants were discussed. Finally, we evaluated some of the challenges of implementing pharmacogenetics in a clinical setting and proposed actions to be taken to make pharmacogenetics a standard diagnostic tool in personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.